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The melanocortin-1 receptor (MCIR) is a G-protein-coupled
receptor expressed primarily in melanocytes and is known to
play a pivotal role in the regulation of pigmentation in mam-
mals. In humans MC1R has been found to be highly polymor-
phic with several functional variants associated with the pheno-
type of redhair color and fair skin, cutaneousUVsensitivity, and
increased risk of developingmelanoma andnon-melanoma skin
cancer. Recent evidence suggests that MC1R plays a photo-pro-
tective role in melanocytes in response to UV irradiation. Rela-
tively fewgenetic targets ofMC1Rsignalinghavebeen identified
independent of the pigmentation pathway. Here we show that
MC1R signaling in B16 mouse melanoma cells and primary
human melanocytes rapidly, and transiently, induces the tran-
scription of the NR4A subfamily of orphan nuclear receptors.
Furthermore, primary human melanocytes harboring homozy-
gous RHC variant MC1R alleles exhibited an impaired induc-
tion of NR4A genes in response to the potent MC1R agonist
(Nle4,D-Phe7)--melanocyte-stimulating hormone. Using
small interference RNA-mediated attenuation of NR4A1 and
NR4A2 expression in melanocytes, the ability to remove
cyclobutane pyrimidine dimers following UV irradiation
appeared to be impaired in the context of MC1R signaling.
These data identify theNR4A receptor family as potentialmedi-
ators of an MC1R-coordinated DNA damage response to UV
exposure in melanocytic cells.
It has long been recognized that individuals with fair skin and
poor tanning ability have an increased incidence of melanoma
and non-melanoma skin cancer (1–3). Cutaneous pigmenta-
tion in humans is the result of melanin synthesis by epidermal
melanocytes within specialized organelles termed melano-
somes, which are transferred to surrounding keratinocytes (4).
Human pigmentation is a polygenic trait with 60 genetic
loci identified so far (5, 6). Efforts over the last decade to under-
stand the genetic basis of human pigmentary traits have
revealed the melanocortin-1 receptor (MC1R)5 as a key deter-
minant of the wide phenotypic diversity in mammals (7–9).
MC1R is a seven-transmembrane G-protein-coupled receptor
that has been found to be highly polymorphic in Caucasian
individuals, with a number of functional variants strongly asso-
ciating with a phenotype of red hair, fair skin, and poor tanning
ability often referred to as the RedHair Color (RHC) phenotype
(7). MC1R preferentially binds the pro-opiomelanocortin-de-
rived peptides -melanocyte-stimulating hormone (-MSH)
and adrenocorticotropic hormone, which leads to an elevation
in intracellular cAMP levels (10). RHC variant MC1Rs have
been demonstrated to elicit weak cAMP responses as a result of
reduced receptor coupling (2, 11–13) or abnormal receptor
localization (2, 12–15). Molecular analysis has revealed that
MC1R signaling modulates the expression and function of the
microphthalmia-associated transcription factor, a key regula-
tor of pigmentation genes, suggesting that this pathway under-
lies MC1R coordination of melanogenesis (16). Accumulating
evidence suggests the photo-protective effect of MC1R sig-
naling goes beyond quantitative and qualitative changes in
melanin synthesis and extends to protection against UV-
induced genomic damage via the induction of nucleotide
excision repair mechanisms (17–19). Although variantMC1R
is anticipated to have a significant effect on melanocyte gene
expression, few downstream transcriptional targets of MC1R sig-
naling have been identified to date (20–22) and the differential
transcriptional response between wild-type and RHC signaling
remains poorly understood.
The NR4A genes are a subfamily of nuclear receptors that
includes NR4A1 (Nur77), NR4A2 (Nurr1), and NR4A3
(NOR-1) in mammals. The nuclear receptor superfamily of
transcriptional regulators includes the classical steroid recep-
tors, the thyroid and retinoid receptors, and a large subgroup of
receptors referred to as “orphan receptors” as no natural or
synthetic hormone/ligands have been identified to date (23, 24).
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TheNR4A subfamily belongs to the orphan receptor subgroup,
and crystal structure analysis suggests these receptors may be
true orphan receptors that are unable to accommodate mole-
cules within their ligand binding domain in the samemanner as
traditional NR ligand binding domains (25, 26). TheNR4A sub-
family was first identified as early response genes for growth
factors (27, 28). All threeNR4A receptors bind toDNA consen-
sus elements termed NBREs as monomers or to a palindromic
NurRE sequence as homo- or heterodimers (29).
NR4A genes have been implicated in a wide range of biolog-
ical processes including proliferation, differentiation, apopto-
sis, and tissue remodeling and in pathologies such as neurolog-
ical disorders including Parkinson disease, schizophrenia and
manic depression, inflammatory and cardiovascular disease,
and cancer (25, 30). Expression and function of the NR4A fam-
ily of nuclear receptors are influenced by a wide range of signal-
ing pathways that utilize a number of signaling cascades to gen-
erate a functional output, including cAMP, MEK/extracellular
signal-regulated kinase (ERK), p38/MAPK, protein kinase C,
and Ca2 (25, 31–33). Recent reports demonstrate the rapid
induction of NR4A genes in macrophage cells in response to
inflammatory stimuli (34) and in hepatic and skeletal muscle
tissueswhere they coordinate pathways involved in glucose and
lipid homeostasis (31–33). Interestingly, reports demonstrat-
ing the activation of NR4A proteins by the purine anti-metab-
olite 6-mercaptopurine and related compounds suggest that
this gene family may be involved in the genotoxic stress
response (35, 36).
The induced expression of NR4A1 has been reported previ-
ously inmelanoma cells in response to interleukin-1 signaling
(37) and has recently been linked to melanoma apoptotic sen-
sitivity (38). The expression and function of the NR4A2 and
NR4A3 genes in melanocytic cells have not been reported to
date. Here we report that all three NR4A receptors are induced
and function immediately downstream of MC1R signaling in
melanocytic cells. Furthermore, we demonstrate the impaired
induction of the NR4A gene family in primary human melano-
cytes of MC1R variant genotype. This observation reveals the
NR4A gene family as one of the immediate transcriptional tar-
gets of MC1R signaling in melanocytic cells. Moreover, the
functional role of this nuclear receptor subfamily inmelanocyte
gene expression remains to be explored.
MATERIALS ANDMETHODS
Cell Culture, UV Irradiation, and Transfection Analysis—
B16 melanoma cells were cultured in RPMI 1640 medium sup-
plemented with 5% fetal bovine serum, 2 mM L-glutamine, and
penicillin (20 units/ml)/streptomycin (20 g/ml). Transfections
using the pGL2B-NurRE luciferase reporter (39) were per-
formed in 24-well tissue culture dishes with 0.8 mg of DNA/
well using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s instructions. Cells were harvested and
analyzed as described previously (31, 40).
Primary humanmelanocytes (QF278, 840, 731, 863, 955, and
1093) were cultured using established protocols (41). Primary
human melanocytes derived from differentiated melanoblasts
(QF1170 and 1160) were cultured and differentiated as
described previously (42). Differentiating melanocytes were
grown on coverslips for 3 days prior to UV irradiation experi-
ments, and cells were transfected with siRNA reagents 24 h
prior to UV irradiation. siRNA reagents were transfected into
cells using Lipofectamine 2000 according to themanufacturer’s
recommendation to a final concentration of 50 nM. siRNA
reagents were: negative control (Ambion), NR4A1 (1:1 pooled
ID41824 and ID41752; Ambion), and NR4A2 (Smartpool;
Dharmacon). Following a 4-h preincubation in medium sup-
plemented with either vehicle or NDP-MSH (10 nM), cells
were irradiated with 25mJ cm2 UVB in phosphate-buffered
saline as described previously (41). Following irradiation, cells
were maintained in vehicle or NDP-MSH-containing medium
for a further 24 h, at which point cells were fixed in 4%
paraformaldehyde and analyzed by immunofluorescence.
RNAAnalysis and Real-time PCR—Total RNAwas extracted
from melanoma cell lines using TRI Reagent (Sigma-Aldrich)
followed byDNase treatment and further purification using the
RNeasy RNA extraction kit (Qiagen) described previously (31,
40). Complementary DNA was synthesized from 1 g of total
RNA using a random hexamer and Superscript III reverse tran-
scriptase (Invitrogen) according to the manufacturer’s instruc-
tions. Target cDNA levels were analyzed by q-RT-PCR using
SYBR Green or TaqMan reagent (ABI) as described previously
(31, 40). Primer sequences are available by request.
Electrophoretic Mobility Shift Assay (EMSA)—Nuclear
extracts were prepared using B16 cells as described previously
(43). EMSA was performed using radiolabeled annealed oligo-
nucleotides containing the NBRE consensus element (44). Oli-
gonucleotide sequences were 5-gggatcctcgtgcgaaaaggtcaagcg-
cta-3 (upper strand), 5-ggttcctggcatttgaggtaaatatcacta-3
(lower strand).
UV Irradiation of Cultured Cells and Immunofluorescence—
Primary human melanoblasts were cultured on coverslips and
differentiated into melanocytes and manipulated as described
above. Immunofluorescence was performed on paraformalde-
hyde-fixed cells to determine nuclear CDP content using an
anti-cyclobutane pyrimidine dimer antibody (TDM-2; MBL
International Corp.) according to the manufacturer’s recom-
mended protocol. For quantification six to eight representative
pictures per coverslip were taken and analyzed in Adobe Pho-
toshop for fluorescence intensity (grey scale). Images were
obtained on an Olympus BX-51 epifluorescence microscope
with a DP-70 camera.
Statistical Analysis—Statistical analysis was performed on a
minimum of three independent experiments using a ratio t test
or one-way analysis of variance followed by a Tukey’s post-test
using GraphPad-PRISM software.
RESULTS
Induction of NR4A Gene Expression by MC1R Signaling in
B16 Melanoma—We first analyzed the NR4A class of nuclear
receptors as potential target genes ofMC1R signaling using B16
mouse melanoma cells. B16 cells were chosen as they express
wild-type MC1R with an intact downstream signaling pathway
(45, 46). AsNR4A genes are known to be serum-responsive (25,
26), B16 cells were preincubated for 2 h in serum-free medium,
at which point cells were treated with vehicle or 10 nM NDP-
MSHandRNAharvested at the indicated time points over 36 h.
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Time point RNA samples were analyzed by real-time PCR for
expression of each NR4A family member. This analysis
revealed that the mRNAs encoding the NR4A1–3 genes were
rapidly and transiently induced following NDP-MSH treat-
ment in B16 melanoma cells (Fig. 1). More specifically, NR4A1
and NR4A2 showed maximal induction at 1 h, while maximal
induction ofNR4A3 occurred at 2 h postNDP-MSH treatment.
Analysis of NR4A function in B16 cells in response toMC1R
signaling was performed using a transiently transfected NR4A
reporter construct containing the NurRE consensus element
upstream of the luciferase gene (39). Increased luciferase activ-
ity was detected in B16 cells treated with NDP-MSH compared
with control cells, with maximal activity detected after 6 h in
experiments performed here (Fig. 2A). Furthermore, luciferase
activity was returning to basal levels 24 h post NDP-MSH stim-
ulation, suggesting the NR4A proteins are functioning within
the first 24 h after MC1R activation.
Direct detection of NR4A DNA binding activity in nuclear
extracts generated from B16 cells 8 h after vehicle, NDP-MSH,
or forskolin treatment was performed by EMSA. Comparison
of DNA-protein complexes bound to an NBRE consensus ele-
ment (44) in these studies demonstrated an increased binding
activity in both NDP-MSH- and forskolin-treated cells when
comparedwith the vehicle control (Fig. 2B). These data confirm
increased NR4AmRNA and protein expression and functional
activity in B16 cells occurs immediately downstream of MC1R
signaling.
Cross-talk between the NR4A Nuclear Receptor and MC1R
Signaling Cascades in B16 Melanoma Cells—Although MC1R
signaling functions primarily via the stimulation of adenylate
cyclase resulting in the production of cAMP, emerging evi-
dence suggests that a number of other signaling cascades are
also activated by MC1R in melanocytic cells (10, 41, 47, 48).
Moreover, the NR4A subgroup has been shown to be targets of
cAMP signaling in a number of cell types (25, 26). To identify
the signaling cascades involved in MC1R-mediated induction
of NR4A genes, we stimulated B16melanoma cells with vehicle
or NDP-MSH in the presence of a number of specific signaling
protein inhibitors, including H89 (protein kinase A),
GF10933X (protein kinase C), SB203580 (p38/MAPK), and
FIGURE 1. NR4A genes are induced by MC1R signaling in B16 melanoma
cells. A–C, B16 mouse melanoma cells were preincubated for 2 h in serum-
free medium, at which point cells were treated with vehicle or 10 nM NDP-
MSH and RNA harvested as indicated over a 36-h time course. NR4A gene
expression analysis was performed by q-RT-PCR for expression of NR4A1 (A),
NR4A2 (B), or NR4A3 (C). NDP-MSH-induced q-RT-PCR results were normal-
ized against the glyceraldehyde-3-phosphate dehydrogenase control gene
and converted to -fold induction relative to vehicle treatment for each time
point. Data represent the mean  S.E. of three independent experiments.
Statistical analysis was performed using analysis of variance with a Tukey’s
post-test (***, p 0.001; **, p 0.01; *, p 0.05).
FIGURE 2. Increased NR4A activity by MC1R signaling in B16 melanoma
cells. A, B16 cells were transfected with the pGL2B-NurRE luciferase reporter
construct for 22 h, at which point the cells were supplemented withmedium
containing vehicle or NDP-MSH (10 nM) following a 2-h preincubation in
serum-freemedium. Cells were harvested and analyzed for luciferase expres-
sion at 2, 4, 6, and 24 h post ligand administration. NDP-MSH-induced lucifer-
ase activitywasnormalized to vehicle-treated cells for given timepoints. Data
represent the mean S.E. of three independent experiments. B, EMSA anal-
ysis was used to detect NR4A DNA binding activities in nuclear extracts
obtained fromB16 cells treatedwith vehicle (V), NDP-MSH (M), or forskolin (F)
for 8 h; FP, free probe. A representative experiment from three independent
experiments is shown.
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PD98059 (MEK1/2). As shown in Fig. 3, NDP-MSH-mediated
induction of all threeNR4A genes was observed in the presence
of the vehicle control (DMSO) while attenuation of this
response was observed to varying degrees with the inhibitor
compounds, suggesting multiple signaling cascades are acti-
vated by MC1R (Fig. 3).
Effect of RHC Variants on MC1R-mediated Induction of
NR4A Genes—Given the importance of the MC1R signaling
pathway in human pigmentation and UV protection, we deter-
mined whether the NR4A genes are similarly induced by NDP-
MSH in human melanocytes. To this end, primary human
melanocytes of defined MC1R genotypes were treated with
NDP-MSH or vehicle and analyzed for NR4A induction at 1-
and 3-h time points following administration. Previous reports
have demonstrated the ability of wild-type consensus MC1R
alleles to stimulate the cAMP pathway in response to NDP-
MSH, an effect that is significantly attenuated in the context of
homozygous RHC variant alleles (9, 13, 49). Three melanocyte
strains homozygous for the wild-type MC1R exhibited a
marked induction of theNR4A2gene in response toNDP-MSH
above basal levels (Fig. 4B). By contrast, the levels of NR4A2
expression in homozygousRHCvariantMC1R strainswere sig-
nificantly impaired (Fig. 4B). A comparison of pooled expres-
sion data in these melanocyte strains revealed the differential
induction of NR4A2 expression between the wild-type- and
RHC-expressing melanocytes in response to NDP-MSH was
statistically significant (Fig. 4E). Induction of the NR4A1 and
NR4A3 subtypes in response to NDP-MSH stimulation was
also apparent in wild-type MC1R-expressing melanocytes,
whereas the levels of induced NR4A1 or NR4A3 expression
were lower in the context of RHC variant MC1R (Fig. 4, A and
C). Comparison between pooledWT and RHC expression data
for the NR4A1 and NR4A3 genes revealed a similar trend in
which induction of these family members was reduced in RHC
variant melanocytes relative to the induction levels observed in
the context of WT MC1R (Fig. 4, D and F). In all melanocyte
strains used in this study NR4A gene expression returned to
basal levels 3 h post NDP-MSH stimulation (data not shown).
NR4A Role in MC1R-mediated DNA Repair in Melanocytes—
Recent evidence has shown that MC1R function protects
against DNA damage independently of pigmentation pheno-
type. Given the immediacy of NR4A induction by MC1R sig-
naling, we decided to investigate the effect of attenuated
NR4A1/2 expression on the photo-protective activity ofMC1R.
Cyclobutane pyrimidine (CPD) dimers are a hallmark DNA
lesion induced by ultraviolet radiation. Previous investigations
have revealed that MC1R signaling in melanocytes facilitates
the clearance of UVB-induced cyclobutane pyrimidine dimers,
pointing to an important role for MC1R in protection against
UV-induced mutations that may lead to malignancy (17–19).
Accordingly, we chose to examine the effect of loss of NR4A
gene expression on the ability of MC1R signaling to promote
repair of CPD lesions. First we demonstrated that NR4A1/2
expression induced by MC1R signaling could be attenuated in
primary human melanocytes using NR4A1/NR4A2-specific
siRNAs. Although transfection with a negative siRNA did not
prevent MC1R-mediated induction of NR4A1 and NR4A2
mRNA, the specific siRNAs effectively attenuated induction of
these genes as assessed by real-time PCR (Fig. 5,A and B). Dual
NR4A1 andNR4A2 knock downwas employed in these studies
to avoid potential redundancy between these closely related
receptors. The ability of melanocytes treated in this manner to
remove UVB-induced CPDs in the presence or absence of
NDP-MSH was subsequently investigated.
Primary human melanocytes were transfected with either
negative or pooled NR4A1/2 siRNAs 24 h prior to UVB irradi-
ation. Following a 4-h preincubation with medium containing
either vehicle or NDP-MSH, the melanocytes were irradiated
with 25 mJ cm2, after which they were maintained in vehicle-
or NDP-MSH-containingmedium for a further 24 h. Visualiza-
tion of nuclear CPD content in these experiments by immuno-
fluorescence revealed that NDP-MSH-treated cells exhibited
less fluorescence than vehicle-treated cells in the presence of a
FIGURE3.MC1Rsignaling inducesNR4Ageneexpressionbymultiple sig-
naling cascades. A–C, mouse B16 cells were treated with 10 nM NDP-MSH in
thepresenceofDMSO (V, vehicle control), H89 (10M), GF10933X (GF, 10M),
SB203580 (SB, 20M), or PD98059 (PD, 20M) for 1 h following a 2-h preincu-
bation in serum-freemedium. Total cellular RNAwas isolatedandanalyzedby
q-RT-PCR for NR4A1 (A), NR4A2 (B), andNR4A3 (C) expression. Expressionwas
determined relative to glyceraldehyde-3-phosphate dehydrogenase and
represents the mean  S.E. of three independent experiments. Statistical
analysis was performed using analysis of variancewith a Tukey’s post-test (**,
p 0.01; *, p 0.05). ns, not significant.
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negative siRNA, indicating the clearance of UVB-induced CPD
lesions by MC1R signaling (Fig. 5C, upper panels). Notably, in
cells transfected with the combination of NR4A1 and NR4A2
siRNAs there appeared to be little difference in CPD content
between vehicle and NDP-MSH-treated melanocytes (Fig. 5C,
lower panels). Quantification of the fluorescence intensity of
these cells from three independent experiments confirmed the
attenuated clearance of CPDs by NDP-MSH in cells in which
NR4A1/2 expression had been inhibited (Fig. 5D). Specifically,
there were significantly lower levels of CPDs detected in nega-
tive siRNA-transfected melanocytes following treatment with
NDP-MSHcomparedwith vehicle, whereas therewas little differ-
ence between the levels of CPDs contained in melanocytes in
which NR4A1/2 had been knocked
down.Moreover, there was as signifi-
cant difference in the relative CPD
content between negative siRNA-
and NR4A1/2 siRNA-treated mela-
nocytes in the presence of NDP-
MSH. These data confirm the ability
of MC1R signaling to mediate the
repair of UV-inducedDNA lesions as
reported previously (17–19) and sug-
gests that the ability of MC1R signal-
ing to induce NR4A genes is a vital
component of this process.
DISCUSSION
The activation of signaling path-
ways through -MSH ligand stim-
ulation has long been known to
be a key regulator of constitutive
and UV-induced pigmentation in
humans. The identification of
MC1R as the primary target of the
-MSH peptide in melanocytes in
the last decade, coupled with
genetic association studies, has
highlighted the importance of this
pathway to mammalian pigmenta-
tion (7–9, 50). Despite consider-
able efforts, the physiological
function of MC1R in coordinating
melanocyte pigmentation and
photo-protection remains poorly
understood. The identification of
downstream targets and effectors
of MC1R represents an important
step in advancing our understand-
ing of this pathway. Initial studies
reported here reveal the rapid and
transient induction of the NR4A
family of orphan nuclear receptors
following stimulation of B16
mouse melanoma cells with the
potent MC1R agonist NDP-MSH.
The induction profile of all three
members of this receptor family is
similar to that observed in other systems, with maximal
mRNA expression detected at 1 h for both NR4A1 and
NR4A2 receptors, after which expression levels rapidly
return to basal levels. Expression of the NR4A3 receptor is
similarly induced following NDP-MSH treatment; however,
maximal induction is achieved 2 h after MC1R stimulation and
returns to basal levels after 4 h. The rapid and transient induction
profile observed for these receptors suggests that they are involved
in coordinating the immediate transcriptional response of the
MC1R signaling pathway. Furthermore, increased NR4A DNA
binding activity detected by EMSA coupled with NR4A-respon-
sive reporter assays suggests theNR4A genes are transcriptionally
active within the first 24 h postMC1R receptor stimulation.
FIGURE 4.HumanRHC variantMC1R alleles exhibit impaired induction of NR4A expression. A–C, primary
humanmelanocyteswere cultured and administered vehicle orNDP-MSH (10nM) for 1 h. NR4Aexpressionwas
analyzed by q-RT-PCR (A–C). Data shown are mean  S.D. from a single experiment performed for each cell
strain. D–F, expression data from A–C were pooled to compare NR4A expression levels between WT and RHC
variant melanocytes for NR4A1 (D), NR4A2 (E), and NR4A3 (F). Expression levels are shown for three independ-
entWT strains (QF840,QF863, andQF1093) and three independent RHC variant strains (QF278 (R151C homozy-
gous), QF955 (R160W homozygous), and QF731 (R151C/D294H compound heterozygous)). Statistical analysis
was performed using analysis of variance with a Tukey’s post test (***, p 0.001).
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We analyzed the effect of specific signaling pathway inhibitors
onMC1R-mediatedNR4Agene induction in order to identify sig-
nalingcascades involved inMC1Rsignalingvia theNR4Areceptor
family. While inhibition of the cAMP pathway was anticipated to
attenuate NR4A induction by MC1R signaling, the ability of the
protein kinase C and p38 pathway inhibitors to attenuate NR4A
induction by MC1R activation suggests cross-talk between these
cascades and MC1R signaling. Similar evidence for multiple sig-
naling pathway involvement in NR4A gene induction has been
observed in the context of corticotroph stimulation by corticotro-
phin-releasing hormone/cAMP (51). Moreover, recent reports
have demonstrated cross-talk between MC1R-mediated cAMP
and p38/MAPK signaling pathways (41).
Numerous studies have revealed a significant association
between variant MC1R and cutaneous malignant melanoma
and non-melanoma skin cancer, leading to the conclusion that
MC1R is a skin cancer susceptibility gene (3, 18, 52). In light of
the links between variant and aberrant MC1R signaling and
skin cancer predisposition, it was important to ascertain the
effect of functional variant alleles of
MC1R on induction of NR4A. The
identification of divergent melano-
cyte function in the context of WT
or variant MC1R proteins will pro-
vide vital clues into themechanisms
underlying the association between
MC1R status and pigmentation
phenotype, UV sensitivity, and mel-
anoma/skin cancer susceptibility.
The data presented here reveal that
the induction of NR4A gene expres-
sion is one of the immediate steps in
MC1R signaling in melanocytes
expressing wild-type alleles of
MC1R. Moreover, in melanocyte
strains derived from individuals that
are homozygous for the three most
common RHC variant MC1R alle-
les, R151C, R160W, andD294H, the
induction of NR4A expression in
response to ligand stimulation is
compromised. It is possible that the
impaired NR4A induction by vari-
ant MC1R may underlie to some
extent the susceptibility of RHC
individuals to skin cancer.
Although much of the cutaneous
photo-protective function of the
wild-type MC1R protein is un-
doubtedly attributable to its role in
basal and inducible melanization,
recent reports suggest a protective
role for MC1R against UV-induced
DNA damage independent of pig-
mentation. Human melanocytes
carrying common RHC variants
were found to have impaired clear-
ance ofUV-inducedCPD lesions, an
effect that was independent of the melanin content of the cells
(18). This observation, coupledwithprevious reportsdemonstrat-
ing the reduction of UV-induced CPD lesions byMC1R signaling
(17, 19), suggests that enhancingDNA repair is a vital mechanism
by which the MC1R pathway protects melanocytes from UV-in-
duced mutations. Moreover, MC1R-mediated DNA repair in
response to UV irradiation is an early event and precedes other
MC1R-controlled processes such as melanization.
In light of the fact that NR4A induction by MC1R was an
immediate event following receptor stimulation, and functional
studies suggested these nuclear receptors were transcription-
ally active during the following 24 h, we chose to examine the
effect of loss of NR4A expression on DNA repair in the context
of MC1R signaling. Melanocytes transfected with a negative
control siRNA prior to UVB irradiation exhibited an enhanced
rate of DNA repair in response to NDP-MSH stimulation in
concordance with previous reports demonstrating MC1R-me-
diatedDNA repair (17–19). Importantly, siRNAknock down of
NR4A1 and NR4A2 expression in melanocytes attenuated the
FIGURE 5. NR4A genes regulate MC1R-induced DNA repair. A and B, primary human melanocytes were
transfected with either negative or pooled NR4A1 and NR4A2 (NR4A1/2) siRNAs. 24 h post transfection, cells
were treated with vehicle or 10 nM NDP-MSH and RNA harvested 1 h post treatment. NR4A2 (A) and NR4A1 (B)
expression relative to-2-microglobulin was determined by real-time PCR. Mean S.D. from a representative
experiment. C, primary human melanocytes were transfected with either negative or pooled NR4A1 and
NR4A2 (NR4A1/2) siRNAs. 24 h post transfection cells were treated with vehicle or 10 nM NDP-MSH and irradi-
ated with 25 mJ cm2 UVB following a 4-h preincubation in medium containing vehicle or NDP-MSH (10 nM).
Nuclear CPD content (green) was determined by immunofluorescence. Images are from a representative
experiment. D, The mean  S.E. of the relative quantification of three independent immunofluorescence
experiments (performed twice using the QF1170 strain and once using the QF1160 strain) using Adobe Pho-
toshopgrey scale. Statistical analysiswasperformedusinganalysis of variancewith a Tukey’s post-test (***,p
0.001; *, p 0.05; ns, not significant).
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ability of MC1R signaling to repair UVB-induced CPD lesions.
These data suggest a novel functional link between MC1R-
driven DNA repair and the NR4A nuclear receptor signaling
pathway. This contention is further supported by reports sug-
gesting NR4A genes function as sensors of genotoxic stress
(35). In these reports NR4A proteins were found to be respon-
sive to the purine anti-metabolite 6-mercaptopurine and its
derivatives. The induction of genotoxic stress is a key compo-
nent of the anti-proliferative activity of this class of compound,
leading to the suggestion that theNR4A subgroupmediates the
cellular response to genotoxic stress via the activation of an
NR4A transcriptional response (35). With the emergence of
pharmacological agents capable of targeting the NR4A nuclear
receptors (36, 53–55), further understanding of the cytoprotec-
tive role of this family may have potential implications in the
prevention of melanocytic malignancy.
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